Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11328752 | PMC |
| http://dx.doi.org/10.1016/j.ekir.2024.06.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activating the Flozin Shield: Cardioprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients With Diabetes Mellitus.
Kidney Int Rep
August 2024
Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical Center, New York, New York, USA.
Comparison of SGLT1, SGLT2, and Dual Inhibitor biological activity in treating Type 2 Diabetes Mellitus.
Adv Ther (Weinh)
December 2023
Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, 07102.
Diabetes Mellitus Type 2 (T2D) is an emerging health burden in the USand worldwide, impacting approximately 15% of Americans. Current front-line therapeutics for T2D patients include sulfonylureas that act to reduce A1C and/or fasting blood glucose levels, or Metformin that antagonizes the action of glucagon to reduce hepatic glucose production. Next generation glucomodulatory therapeutics target members of the high-affinity glucose transporter Sodium-Glucose-Linked-Transporter (SGLT) family.
View Article and Find Full Text PDFCardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy.
World J Cardiol
December 2021
Department of Internal Medicine, Methodist Dallas Medical Center, Dallas, TX 75203, United States.
The beneficial cardiorenal outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) have been substantiated by multiple clinical trials, resulting in increased interest in the multifarious pathways by which their mechanisms act. The principal effect of SGLT2i (-flozin drugs) can be appreciated in their ability to block the SGLT2 protein within the kidneys, inhibiting glucose reabsorption, and causing an associated osmotic diuresis. This ameliorates plasma glucose elevations and the negative cardiorenal sequelae associated with the latter.
View Article and Find Full Text PDFMetformin - a new old drug.
Endokrynol Pol
January 2018
Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland.
For many years metformin has been the gold standard in the treatment of type 2 diabetes. According to recommendations of the most important diabetes associations, this is the first-choice drug for use as monotherapy in patients with newly diagnosed type 2 diabetes. Metformin is also recommended in combined treatment when monotherapy is no longer effective.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!